On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the October 2021 CRG meeting.
Actions in this consultation include:
- Inhaled colistimethate, dornase alfa and tobramycin for cystic fibrosis in children – RED. Repatriation should not be sought until a request to do so has been received from the specialist.
- Bimekizumab for moderate to severe plaque psoriasis – RED.
- Link to NG191, Managing COVID-19, to be added to formulary in chapter 2
To take part in this consultation, visit the consultations page. This consultation period is open until 5pm Tuesday 30th November 2021.